More than a century after insulin was discovered, millions of people living with type 1 diabetes continue to face barriers to accessing the lifesaving treatment they need.
This has prompted the World Health Organization (WHO) to issue its first-ever guidelines for diagnosing and managing the condition in adults.
Released to mark World Diabetes Day 2026, the guidelines provide evidence-based recommendations for treating type 1 diabetes across all healthcare settings, including resource-poor countries, emergency situations and humanitarian crises.
The move comes as the global burden of type 1 diabetes continues to grow. An estimated 9.5 million people were living with the condition worldwide in 2025, with another 500,000 diagnosed during the year.
Although type 1 diabetes is often associated with childhood, the WHO says the condition is increasingly affecting adults, underscoring the need for stronger diagnosis, treatment and long-term care.
“Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin,” said Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health.
“The new WHO guidelines provide evidence-based recommendations to help countries deliver the best possible care, including in settings where resources are limited and health services are disrupted.”
Under the new recommendations, people with type 1 diabetes should receive multiple daily insulin injections, with doses adjusted according to blood glucose levels.
The WHO identifies human insulin — a manufactured medicine that mimics the insulin naturally produced by the body — as an appropriate and effective treatment option. Other forms of insulin can also be used when clinically necessary.
The guidelines also stress the importance of regular blood glucose monitoring to help people manage the condition and prevent complications.
Monitoring can include laboratory tests that measure average blood sugar levels over several months, as well as at-home testing through finger-prick blood tests or continuous glucose monitors, which use small sensors worn on the skin. Where blood glucose testing is unavailable, urine glucose testing may be considered.
The recommendations are also aimed at accelerating progress towards WHO targets for 2030, which seek to ensure that everyone living with type 1 diabetes has access to affordable insulin treatment and blood glucose self-monitoring.
To support implementation, the WHO will provide countries with practical tools and guidance to monitor progress. Governments are also being urged to involve people living with type 1 diabetes in designing, implementing and evaluating national diabetes programmes.
The guidelines come as the WHO highlights the urgent need for early detection and intervention under the theme of World Diabetes Day 2026: “Early action on diabetes”.
Diabetes can trigger a range of life-threatening complications, including blindness, kidney failure, heart attacks, strokes and lower-limb amputations.
The scale of the crisis is growing. The global diabetes burden has more than quadrupled since 1990. In 2022, an estimated 830 million people were living with diabetes worldwide, most of them with type 2 diabetes.
Alarmingly, more than 40% of people with diabetes do not know they have the condition, leaving millions undiagnosed and potentially without the treatment and care needed to prevent serious complications.